Zhonghua H. Tao

Shanghai, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications

Prominin 2 promotes the progression of breast cancer by inhibiting ferroptosis via MAPK signaling.

Prominin 2 promotes the progression of breast cancer by inhibiting ferroptosis via MAPK signaling.

Journal: Journal of translational internal medicine
Published: August 27, 2026

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 04, 2026

Human Pancreatic Cancer Organoids.

Human Pancreatic Cancer Organoids.

Journal: Cell proliferation
Published: March 02, 2026

A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer.

A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer.

Journal: ESMO open
Published: August 27, 2025

Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial.

Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial.

Journal: JAMA oncology
Published: July 31, 2025

Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China.

Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China.

Journal: EClinicalMedicine
Published: July 31, 2025

Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy.

Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy.

Journal: Precision clinical medicine
Published: July 19, 2025

Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China.

Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China.

Journal: Therapeutic advances in medical oncology
Published: July 14, 2025

Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer.

Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer.

Journal: Nature communications
Published: July 13, 2025

Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways.

Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways.

Journal: Cancer cell
Published: June 04, 2025

MYC amplification sensitizes TNBC to CHK1 inhibitors.

MYC amplification sensitizes TNBC to CHK1 inhibitors.

Journal: Cellular signalling
Published: December 09, 2024

Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial.

Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial.

Journal: PLoS medicine
Published: October 25, 2024
Showing 1-12 of 73

Last Updated: 09/26/2026